These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 16912914)

  • 1. Effects of the RANKL inhibitor, osteoprotegerin, on the pain and histopathology of bone cancer in rats.
    Roudier MP; Bain SD; Dougall WC
    Clin Exp Metastasis; 2006; 23(3-4):167-75. PubMed ID: 16912914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A rat model of bone cancer pain.
    Medhurst SJ; Walker K; Bowes M; Kidd BL; Glatt M; Muller M; Hattenberger M; Vaxelaire J; O'Reilly T; Wotherspoon G; Winter J; Green J; Urban L
    Pain; 2002 Mar; 96(1-2):129-40. PubMed ID: 11932069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin.
    Li X; Ominsky MS; Stolina M; Warmington KS; Geng Z; Niu QT; Asuncion FJ; Tan HL; Grisanti M; Dwyer D; Adamu S; Ke HZ; Simonet WS; Kostenuik PJ
    Bone; 2009 Oct; 45(4):669-76. PubMed ID: 19539794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer.
    Takayama K; Inoue T; Narita S; Maita S; Huang M; Numakura K; Tsuruta H; Saito M; Maeno A; Satoh S; Tsuchiya N; Habuchi T
    Cancer Lett; 2017 Jul; 397():103-110. PubMed ID: 28373003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of genistein and zoledronic acid on the bone loss in OPG-deficient mice.
    Liu J; Xu K; Wen G; Guo H; Li S; Wu X; Dai R; Sheng Z; Liao E
    Bone; 2008 May; 42(5):950-9. PubMed ID: 18337202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RANKL inhibition through osteoprotegerin blocks bone loss in experimental periodontitis.
    Jin Q; Cirelli JA; Park CH; Sugai JV; Taba M; Kostenuik PJ; Giannobile WV
    J Periodontol; 2007 Jul; 78(7):1300-8. PubMed ID: 17608585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis.
    Zheng Y; Zhou H; Brennan K; Blair JM; Modzelewski JR; Seibel MJ; Dunstan CR
    Bone; 2007 Feb; 40(2):471-8. PubMed ID: 17092788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoprotegerin is an effective countermeasure for spaceflight-induced bone loss in mice.
    Lloyd SA; Morony SE; Ferguson VL; Simske SJ; Stodieck LS; Warmington KS; Livingston EW; Lacey DL; Kostenuik PJ; Bateman TA
    Bone; 2015 Dec; 81():562-572. PubMed ID: 26318907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
    Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
    Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
    Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
    Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of modified sijunzi decoction on the bone metabolism of adriamycin induced nephropathy rats].
    Zheng J; Liu JL; Lin MF; Wang ZF; Liu CY; Wu XH; Lin HY; Chen CF; Zheng XM; Chen XY
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Oct; 33(10):1376-81. PubMed ID: 24432683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis.
    Canon JR; Roudier M; Bryant R; Morony S; Stolina M; Kostenuik PJ; Dougall WC
    Clin Exp Metastasis; 2008; 25(2):119-29. PubMed ID: 18064531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-RANKL treatment improves screw fixation in cancellous bone in rats.
    Bernhardsson M; Sandberg O; Aspenberg P
    Injury; 2015; 46(6):990-5. PubMed ID: 25744169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats.
    Ominsky MS; Li X; Asuncion FJ; Barrero M; Warmington KS; Dwyer D; Stolina M; Geng Z; Grisanti M; Tan HL; Corbin T; McCabe J; Simonet WS; Ke HZ; Kostenuik PJ
    J Bone Miner Res; 2008 May; 23(5):672-82. PubMed ID: 18433301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses.
    Stolina M; Dwyer D; Ominsky MS; Corbin T; Van G; Bolon B; Sarosi I; McCabe J; Zack DJ; Kostenuik P
    J Immunol; 2007 Dec; 179(11):7497-505. PubMed ID: 18025194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis.
    Wittrant Y; Théoleyre S; Chipoy C; Padrines M; Blanchard F; Heymann D; Rédini F
    Biochim Biophys Acta; 2004 Sep; 1704(2):49-57. PubMed ID: 15363860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RANKL inhibition: a novel strategy to decrease femoral head deformity after ischemic osteonecrosis.
    Kim HK; Morgan-Bagley S; Kostenuik P
    J Bone Miner Res; 2006 Dec; 21(12):1946-54. PubMed ID: 17002576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys.
    Ominsky MS; Kostenuik PJ; Cranmer P; Smith SY; Atkinson JE
    Osteoporos Int; 2007 Aug; 18(8):1073-82. PubMed ID: 17384898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OPG-Fc treatment in growing pigs leads to rapid reductions in bone resorption markers, serum calcium, and bone formation markers.
    Sipos W; Zysset P; Kostenuik P; Mayrhofer E; Bogdan C; Rauner M; Stolina M; Dwyer D; Sommerfeld-Stur I; Pendl G; Resch H; Dall'Ara E; Varga P; Pietschmann P
    Horm Metab Res; 2011 Dec; 43(13):944-9. PubMed ID: 22161252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The receptor activator of nuclear factor-kappaB ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism.
    Padagas J; Colloton M; Shalhoub V; Kostenuik P; Morony S; Munyakazi L; Guo M; Gianneschi D; Shatzen E; Geng Z; Tan HL; Dunstan C; Lacey D; Martin D
    Calcif Tissue Int; 2006 Jan; 78(1):35-44. PubMed ID: 16362459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.